| Identification | Back Directory | [Name]
3-Pyridinecarboxamide, N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-(4-isothiazolyl)- | [CAS]
2240191-12-0 | [Synonyms]
BCR-ABL-IN-3
3-Pyridinecarboxamide, N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-(4-isothiazolyl)- | [Molecular Formula]
C20H17ClF2N4O3S | [MOL File]
2240191-12-0.mol | [Molecular Weight]
466.89 |
| Hazard Information | Back Directory | [Uses]
BCR-ABL-IN-3 is a potent and irreversible Bcr-Abl inhibitor with an IC50 of ≤100 nM for Ba/F3Bcr-AblT3151. BCR-ABL-IN-3 has anti-cancer activity[1]. | [in vivo]
BCR-ABL-IN-3 (compound 7; 15 mg/kg; twice a day; for 19 days) has good antitumor effect in female NOD/SCID mice of 7-8 weeks weighing 21.8 g with Ba/F3Bcr-AblT3151 cells[1].
BCR-ABL-IN-3 (2 mg/kg for IV or 20mg/kg for PO) has a Cmax of 5485 ng/mL and an AUC of 5450 h?ng/mL for IV in male Sprague Dawley rats of 7-8 weeks old weighing 210 g[1].
| [IC 50]
Ba/F3Bcr-AblT3151: ≤100 nM (IC50) | [References]
[1] Hanyi Wang, et al. (hetero)arylamide compound for inhibiting protein kinase activity. WO2018133826A1. |
|
|